Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes

被引:137
作者
Martino, R
Caballero, MD
Simón, JAP
Canals, C
Solano, C
Urbano-Ispízua, A
Bargay, J
Léon, A
Sarrá, J
Sanz, GF
Moraleda, JM
Brunet, S
San Miguel, J
Sierra, J
机构
[1] Hosp Santa Creu & Sant Pau, Serv Hematol Clin, Div Clin Hematol, Barcelona 08025, Spain
[2] Hosp Clin Barcelona, Div Clin Hematol, Barcelona, Spain
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Univ Valencia, Hosp Clin, E-46003 Valencia, Spain
[5] Hosp La Fe, E-46009 Valencia, Spain
[6] Hosp Son Dureta, Palma de Mallorca, Spain
[7] Hosp SAS Jerez de la Frontera, Jerez de la Frontera, Spain
[8] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[9] Hosp Morales Meseguer, Murcia, Spain
关键词
D O I
10.1182/blood-2002-02-0400
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report the results of a prospective study of a reduced-intensity conditioning (RIC) regimen followed by allogeneic peripheral blood stem, cell transplantation (PBSCT) from an HILA-identical sibling in 37 patients with acute myeloid leukemia (AML; n=17) or myelodysplastic syndrome (MDS; n=20). The median age was 57 years, and 22 (59%) were beyond the early phase of their disease. The incidence of grade II to IV acute graft-versus-host disease (GVHD) was 19% (5% grade III-IV), and the 1-year incidence of chronic extensive GVHD was 46%. With a median follow-up of 297 days (355 days in 24 survivors), the 1-year probability of transplant-related mortality was 5%, and the 1-year progression-free survival was 66%. The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P=.008). These results suggest that a graft-versus-leukemia effect plays a crucial role in reducing the risk of relapse after a RIC allograft in AML and MDS.
引用
收藏
页码:2243 / 2245
页数:3
相关论文
共 21 条
[1]  
Bacigalupo A, 2000, BRIT J HAEMATOL, V108, P99
[2]  
BACIGALUPO A, 1991, BLOOD, V77, P1423
[3]  
Carella AM, 2000, HAEMATOLOGICA, V85, P304
[4]   Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [J].
de Witte, T ;
Hermans, J ;
Vossen, J ;
Bacigalupo, A ;
Meloni, G ;
Jacobsen, N ;
Ruutu, T ;
Ljungman, P ;
Gratwohl, A ;
Runde, V ;
Niederwieser, D ;
van Biezen, A ;
Devergie, A ;
Cornelissen, J ;
Jouet, JP ;
Arnold, R ;
Apperley, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :620-630
[5]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[6]   Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation [J].
Giralt, S ;
Thall, PF ;
Khouri, I ;
Wang, XM ;
Braunschweig, I ;
Ippolitti, C ;
Claxton, D ;
Donato, M ;
Bruton, J ;
Cohen, A ;
Davis, M ;
Andersson, BS ;
Anderlini, P ;
Gajewski, J ;
Kornblau, S ;
Andreeff, M ;
Przepiorka, D ;
Ueno, NT ;
Molldrem, J ;
Champlin, R .
BLOOD, 2001, 97 (03) :631-637
[7]  
GIRALT S, 2001, IBMTR ABMTR NEWSLETT, V8, P5
[8]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[9]  
2-F
[10]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088